Vitality Watch

Dossier pubmed review 26-sep-2026
Narrative review or expert overview without new data

Recent advances in metabolism and applications of medium-chain triglycerides in neurodegenerative diseases.

Key claim: Medium-chain triglycerides can increase ketone availability and may improve selected metabolic or cognitive outcomes relevant to neurodegenerative disease and functional healthspan, though clinical benefits remain inconsistent.

Abstract

Medium-chain triglycerides (MCTs) have attracted considerable interest in functional foods and nutrition due to their rapid and efficient metabolism. Emerging evidence indicates that MCTs can enhance cerebral energy metabolism, supporting interest in their potential role in nutritional strategies for neurodegenerative diseases and the maintenance of neurological function during healthy aging. This review examines the neuroprotective potential of MCTs from the perspectives of metabolism and application. It elucidates the distinctive metabolic pathways of MCTs, emphasizing their ability to supply alternative energy substrates to the brain through medium-chain fatty acids and ketone body production. Recent advances in chain-length-specific MCT formulations are also summarized, along with their applications in nutritional supplementation. Key challenges and future research directions are discussed, including further investigation into the chain-length-specific effects of MCTs, the need for standardized clinical validation, and rigorous safety assessment. Overall, current evidence suggests that MCT-based interventions can increase ketone availability and may improve selected metabolic or cognitive outcomes, suggesting potential relevance to maintaining functional healthspan, although clinical benefits remain inconsistent. These insights aim to inform future research and the development of MCT-based nutritional strategies for age-related diseases, particularly neurodegenerative diseases.

Why this matters

Medium-chain triglycerides can increase ketone availability and may improve selected metabolic or cognitive outcomes relevant to neurodegenerative disease and functional healthspan, though clinical benefits remain inconsistent.

Source

Link

Briefing card

Recent advances in metabolism and applications of medium-chain triglycerides in neurodegenerative diseases.
Stage: review · pubmed · 26-sep-2026

Medium-chain triglycerides can increase ketone availability and may improve selected metabolic or cognitive outcomes relevant to neurodegenerative disease and functional healthspan, though clinical benefits remain inconsistent.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1080/10408398.2026.2737560

build build 880 · 2bcef25 · 2026-11-18